A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study

Published:2019-12-10 Issue:4 Volume:25 Page:720-731
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Matsubara Nobuaki,Kimura Go,Uemura Hiroji,Uemura Hirotsugu,Nakamura Motonobu,Nagamori Satoshi,Mizokami Atsushi,Kikukawa Hiroaki,Hosono Makoto,Kinuya Seigo,Krissel Heiko,Siegel Jonathan,Kakehi Yoshiyuki

Funder

Bayer CropScience

Bayer

Astellas Pharma

Janssen Pharmaceuticals

Takeda Pharmaceutical Company

AstraZeneca

Sanofi

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-019-01589-6.pdf

Reference24 articles.

1. Zhang T, Zhu J, George DJ et al (2015) Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opin Pharmacother 16:473–485

2. Zuo M, Xu X, Li T et al (2016) Progress in the mechanism and drug development of castration-resistant prostate cancer. Future Med Chem 8:765–788

3. Suominen MI, Fagerlund KM, Rissanen JP et al (2017) Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res 23:4335–4346

4. Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223

5. Nilsson S, Cislo P, Sartor O et al (2016) Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 27:868–874

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Japanese clinical practice guidelines for prostate cancer 2023;International Journal of Urology;2024-07-30

2. A Systematic Review of Patient Race, Ethnicity, Socioeconomic Status, and Educational Attainment in Prostate Cancer Treatment Randomised Trials—Is the Evidence Base Applicable to the General Patient Population?;European Urology Open Science;2023-08

3. N-Acetylcysteine Attenuates the Prednisolone-Induced Osteoporosis via Rescuing the Nuclear Factor Erythroid 2-Related Factor 2-Antioxidant Responsive Element Axis Activity in Mice;Journal of Biomedical Nanotechnology;2023-04-01

4. Tailoring radiotherapies and nanotechnology for targeted treatment of solid tumors;Coordination Chemistry Reviews;2022-12

5. Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study;International Journal of Urology;2022-08-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3